SWOT Analysis
- S
- W
- O
- T
-
Strength (4)
Stocks with high EPS and EPS growth TTM and YoY
-
Weakness (4)
Low Piotroski Score Companies
-
Opportunity (1)
FII / FPI or Institutions increasing their shareholding
-
Threats (0)
- Companies with high TTM EPS Growth
- Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
- Increasing Revenue every quarter for the past 2 quarters
- Companies with Zero Promoter Pledge
- FII / FPI or Institutions increasing their shareholding
Technical Analysis
Moving Averages
- 5 Day 138.3
- 10 Day 141.1
- 12 Day 142.2
- 20 Day 145.6
- 26 Day 147.7
- 50 Day 153.2
- 100 Day 159.0
- 200 Day 169.0
Current Price
- Bullish Moving Averages 0
- Bearish Moving Averages 16
Resistance and support
- First Resistance 141.9
- Second Resistance 147.0
- Third Resistance 149.9
- First Support 133.8
- Second Support 130.9
- Third Support 125.8
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 12.06%
- 9.67%
- 15.71%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 898.56 | 868.86 | 829.68 | 708.02 | 646.80 |
|
| Operating Profit | 145.76 | 157.02 | 179.01 | 143.29 | 126.82 |
|
| OP Profit Margin | 16.22 | 18.07 | 21.58 | 20.24 | 19.61 |
|
| Interest | 14.48 | 12.66 | 4.32 | 4.44 | 4.40 |
|
| Profit After Tax | 112.91 | 83.79 | 103.84 | 80.81 | 69.81 |
|
| Cash Profit | 157.14 | 123.64 | 140.99 | 117.87 | 114.29 |
|
| EPS | 10.50 | 7.80 | 9.67 | 7.53 | 6.46 |
|
- CAGR IN 10 YEARS
- 19.10%
- -9.56%
- 12.50%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 107.52 | 107.49 | 107.41 | 107.31 | 108.01 |
|
| Reserve Surplus | 1,139.42 | 1,026.51 | 954.76 | 863.01 | 798.71 |
|
| TOT Debts | 131.46 | 109.86 | 121.48 | 34.08 | 41.31 |
|
| Gross Block | 949.66 | 867.72 | 850.53 | 817.11 | 805.54 |
|
| Capital Work In Progress | 0.26 | 8.04 | 5.24 | 10.05 | 5.74 |
|
| Cash Liquid Investment | 13.39 | 21.66 | 9.23 | 3.32 | 104.40 |
|
| Net Working Capital | 102.85 | 18.51 | 22.81 | 25.85 | 214.50 |
|
| Current Assets | 318.07 | 249.09 | 249.64 | 253.85 | 435.98 |
|
| Current Liabilities | 215.21 | 230.58 | 226.84 | 228.00 | 221.48 |
|
Jun 2026 (CR) |
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 253.79 | 224.85 | 215.24 | 223.97 | 236.65 |
|
| Gross Profit | 44.69 | 34.00 | 31.87 | 40.50 | 49.78 |
|
| Gross Profit Margins | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
|
| Operating Profit | 42.48 | 30.76 | 29.64 | 38.97 | 46.85 |
|
| OP Profit Margin | 14.57 | 11.49 | 11.81 | 15.56 | 18.04 |
|
| Interest | 3.08 | 2.36 | 3.55 | 4.28 | 2.58 |
|
| Profit After Tax | 25.07 | 53.67 | 13.79 | 19.75 | 25.70 |
|
| Cash Profit | 35.87 | 64.20 | 23.79 | 29.69 | 35.38 |
|
| EPS | 2.33 | 4.99 | 1.28 | 1.84 | 2.39 |
|
- CAGR IN 10 YEARS
- 19.10%
- -9.56%
- 12.50%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 12.13 | 25.54 | 24.89 | 17.99 | 18.07 |
|
| P/BV | 1.10 | 1.89 | 2.43 | 1.50 | 1.39 |
|
| MCAP Sales | 1.52 | 2.46 | 3.12 | 2.05 | 1.95 |
|
| Asset Turnover | 0.68 | 0.71 | 0.75 | 0.71 | 0.69 |
|
| EV/EBITDA | 8.72 | 11.90 | 13.50 | 9.12 | 8.57 |
|
| DEBT/EQUITY | 0.10 | 0.11 | 0.08 | 0.04 | 0.05 |
|
| ROE | 9.48 | 7.63 | 10.22 | 8.61 | 7.95 |
|
| ROCE | 9.86 | 12.10 | 14.70 | 12.67 | 11.07 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Shalby Ltd.
Healthcare Facilities company Shalby announced Q1FY27 results
Consolidated Financial Highlights:
- Total Income: The company reported a Total Income of Rs 3,386.38 million in Q1FY27, representing a growth of 14.59% QoQ from Rs 2,955.24 million in Q4FY26 and an 11.60% YoY increase from Rs 3,034.34 million in Q1FY26.
- Revenue from Operations: Revenue for Q1FY27 stood at Rs 3,312.24 million, an increase of 15.23% QoQ compared to Rs 2,874.45 million in Q4FY26 and 11.74% YoY growth compared to Rs 2,964.26 million in Q1FY26.
- Profit Before Tax (PBT): PBT for Q1FY27 reached Rs 196.95 million, rising significantly by 105.03% QoQ from Rs 96.06 million in Q4FY26, though it declined by 13.06% YoY from Rs 226.53 million in Q1FY26.
- Net Profit (after tax): The company earned a net profit of Rs 104.96 million in Q1FY27, which was a 43.12% decrease QoQ from Rs 184.54 million in Q4FY26, but marked a 36.70% increase YoY from Rs 76.78 million in Q1FY26.
- Earnings Per Share (EPS): Basic and Diluted EPS for Q1FY27 was Rs 0.98, compared to Rs 1.72 in Q4FY26 and Rs 0.71 in Q1FY26.
Standalone Financial Highlights:
- Total Income: Standalone Total Income was Rs 2,590.66 million in Q1FY27, up 12.42% QoQ from Rs 2,304.46 million in Q4FY26 and 6.97% YoY from Rs 2,421.77 million in Q1FY26.
- Revenue from Operations: Standalone revenue for Q1FY27 was Rs 2,537.91 million, reflecting a growth of 12.87% QoQ from Rs 2,248.54 million in Q4FY26 and 7.28% YoY from Rs 2,365.64 million in Q1FY26.
- Profit Before Tax (PBT): Standalone PBT reached Rs 338.85 million in Q1FY27, an increase of 44.42% QoQ from Rs 234.62 million in Q4FY26, but a decrease of 15.50% YoY from Rs 401.01 million in Q1FY26.
- Net Profit (after tax): Standalone net profit stood at Rs 250.66 million in Q1FY27, decreasing by 53.30% QoQ from Rs 536.68 million in Q4FY26 and 2.45% YoY from Rs 256.95 million in Q1FY26.
Business Highlights:
- Segment-wise Performance (Consolidated):
- Healthcare Services: This segment recorded a revenue of Rs 2,888.14 million in Q1FY27, up 16.82% QoQ from Rs 2,472.32 million and 7.62% YoY from Rs 2,683.63 million. The segment result (profit before tax) was Rs 311.76 million.
- Manufacturing & Trading of Implants: Segment revenue grew to Rs 424.10 million in Q1FY27, up 5.46% QoQ from Rs 402.13 million and 51.13% YoY from Rs 280.62 million. The segment recorded a result (loss) of Rs 114.81 million.
- Subsidiary Acquisition: Shalby Medtech Limited acquired the remaining 0.67% equity share capital (10,000 shares) of Shalby Global Technologies Pte. Ltd. (SGTPL), Singapore, for a total cash consideration of SGD 20,000. Post-acquisition, SGTPL has become a 100% wholly-owned subsidiary.
- Executive Appointment: The Board approved the appointment of Mr. Shanay Vikram Shah as an Additional Director, designated as a Whole-Time Director, for a term of five consecutive years effective August 12, 2026.
- Internal Audit Appointment: M/s. PricewaterhouseCoopers Services LLP has been appointed as the Internal Auditors of the company for the financial year FY27.
- Employee Stock Options: The company granted 1,33,000 stock options from its lapsed pool during the quarter. As of June 30, 2026, a total of 1,10,000 stock options remain active.
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Shalby Ltd | 136.70 | 1,476.49 | -48.54 | 0.17 | 39.54 | Mar 2026 |
| Manipal Health Enterprises Ltd | 746.10 | 98,140.29 | 11.87 | - | 108.31 | Mar 2026 |
| Molbio Diagnostics Ltd | 1,263.80 | 14,564.03 | 21.32 | - | 88.84 | Mar 2026 |
| Park Medi World Ltd | 285.10 | 12,314.35 | 92.70 | 0.13 | 41.51 | Mar 2026 |
| Suven Life Sciences Ltd | 335.45 | 9,478.57 | 44.40 | 0.23 | -26.93 | Mar 2026 |
| Nephrocare Health Services Ltd | 749.45 | 7,536.40 | 59.03 | 0.10 | 88.57 | Mar 2026 |
| Kovai Medical Center & Hospital Ltd | 6,153.50 | 6,731.93 | 12.13 | - | 26.29 | Mar 2026 |
| Artemis Medicare Services Ltd | 340.85 | 5,395.87 | 37.90 | 0.10 | 47.40 | Mar 2026 |
| Vimta Labs Ltd | 610.15 | 2,727.36 | -20.16 | 0.16 | 34.20 | Mar 2026 |
| KMC Speciality Hospitals (India) Ltd | 159.61 | 2,603.24 | 11.51 | - | 46.73 | Mar 2026 |
| Dr Agarwals Eye Hospital Ltd | 5,200.00 | 2,513.07 | 8.61 | 0.03 | 33.01 | Mar 2026 |
| Suraksha Diagnostic Ltd | 353.40 | 1,840.53 | 10.33 | 0.14 | 52.50 | Mar 2026 |
| Krsnaa Diagnostics Ltd | 557.85 | 1,809.59 | -35.01 | - | 18.59 | Mar 2026 |
| Tarsons Products Ltd | 331.50 | 1,763.79 | 7.46 | - | 158.56 | Mar 2026 |
| Gujarat Kidney & Super Speciality Ltd | 175.17 | 1,381.10 | 67.56 | 0.13 | 82.90 | Mar 2025 |
| GPT Healthcare Ltd | 162.79 | 1,335.77 | 7.84 | 0.09 | 28.25 | Mar 2026 |
| 3B Blackbio DX Ltd | 1,369.30 | 1,175.23 | 5.18 | 0.09 | 20.85 | Mar 2025 |
| One Global Service Provider Ltd | 547.90 | 1,070.76 | -3.08 | - | 14.53 | Mar 2026 |
| Laxmi Dental Ltd | 193.18 | 1,063.06 | -42.68 | 0.15 | 34.36 | Mar 2026 |
| Gaudium IVF and Women Health Ltd | 111.35 | 810.48 | 38.74 | 0.31 | 34.94 | Mar 2025 |
| Lotus Eye Hospital & Institute Ltd | 114.97 | 239.10 | -6.25 | 0.12 | 1660.71 | Mar 2026 |
| Take Ltd | 15.84 | 234.33 | 50.86 | 0.33 | 18.24 | Mar 2026 |
| Sunil Healthcare Ltd | 75.80 | 77.73 | 10.98 | - | 20.76 | Mar 2025 |
| Deccan Health Care Ltd | 11.38 | 0.00 | -43.04 | - | 11.05 | Mar 2025 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Announcement under Regulation 30 (LODR)-Change in Management
Sep 12, 2026Cessation of Mr. Shanay Vikram Shah as Additional Director designated as Whole-time Director of the Company w.e.f. September 10 2026
Shalby Limited - Shareholders meeting
Sep 11, 2026Shalby Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 10, 2026. Further, the company has informed the Exchange regarding voting results.
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Sep 11, 2026Scrutinizer report of Annual General Meeting held on September 10 2026 and voting results.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Sep 10, 2026Outcome and Proceeding of 22nd Annual General Meeting held on 10th September 2026
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-08-12 | Quarterly Results | (Revised) |
| 2026-05-27 | Audited Results & Final Dividend | |
| 2026-02-11 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-13 | Quarterly Results | |
| 2025-05-29 | Audited Results & Final Dividend | |
| 2025-02-03 | Quarterly Results & Others | To consider other business matters. |
| 2024-10-30 | Quarterly Results | |
| 2024-07-08 | Quarterly Results | |
| 2024-05-28 | Audited Results & Final Dividend | |
| 2024-02-07 | Quarterly Results | |
| 2023-10-27 | Quarterly Results | |
| 2023-07-20 | Quarterly Results | |
| 2023-05-18 | Audited Results & Final Dividend | (Revised) |
| 2023-01-17 | Quarterly Results | |
| 2022-10-18 | Quarterly Results | |
| 2022-07-26 | Quarterly Results | |
| 2022-05-25 | Audited Results & Final Dividend | |
| 2022-02-02 | Quarterly Results | |
| 2021-10-26 | Quarterly Results | |
| 2021-08-09 | Quarterly Results | |
| 2021-05-05 | Audited Results & Dividend | |
| 2021-01-08 | Quarterly Results | |
| 2020-10-12 | Quarterly Results | |
| 2020-09-28 | Right Issue of Equity Shares | |
| 2020-09-05 | Quarterly Results | |
| 2020-06-15 | Audited Results & Final Dividend | |
| 2020-02-03 | Quarterly Results | |
| 2019-11-11 | Quarterly Results | |
| 2019-07-29 | Quarterly Results | |
| 2019-05-25 | Audited Results & Dividend | (Revised) |
| 2019-05-18 | Audited Results | |
| 2019-01-28 | Quarterly Results | |
| 2018-10-25 | Quarterly Results | |
| 2018-08-13 | Quarterly Results | |
| 2018-05-07 | Audited Results | |
| 2018-01-09 | Quarterly Results |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 2024-09-19 | 1.2 | FINAL | Equity Share | |
| 2023-08-08 | 1.2 | FINAL | Equity Share | |
| 2022-09-19 | 1 | FINAL | Equity Share | |
| 2021-09-17 | 1 | FINAL | Equity Share | |
| 2020-09-04 | 0.5 | FINAL | Equity Share | |
| 2019-08-16 | 0.5 | FINAL | Equity Share |
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Graviton Research Capital Llp | Bulk | 2025-09-22 |
Purchase |
266.34 | 1,354,105 | NSE |
| Graviton Research Capital Llp | Bulk | 2025-09-22 |
Sell |
266.55 | 1,354,105 | NSE |
| Nk Securities Research Private Limited | Bulk | 2025-09-05 |
Purchase |
223.40 | 568,902 | NSE |
| Musigma Securities | Bulk | 2025-09-05 |
Purchase |
223.24 | 548,438 | NSE |
| Nk Securities Research Private Limited | Bulk | 2025-09-05 |
Sell |
223.57 | 568,902 | NSE |
| Musigma Securities | Bulk | 2025-09-05 |
Sell |
223.36 | 548,438 | NSE |
| First Water Fund | Bulk | 2025-06-13 |
Purchase |
180.00 | 700,000 | NSE |
| Haresh Tikamdas Kaswani | Bulk | 2025-06-13 |
Sell |
180.00 | 700,000 | NSE |
| First Water Fund | Block | 2025-06-13 |
Purchase |
180.00 | 700,000 | NSE |
| Haresh Tikamdas Kaswani | Block | 2025-06-13 |
Sell |
180.00 | 700,000 | NSE |
| Equity Intelligence India Private Limited | Bulk | 2023-03-28 |
Purchase |
117.00 | 610,000 | NSE |
| Shalby Limited Employees Welfare Trust | Bulk | 2022-05-30 |
Purchase |
107.50 | 700,000 | NSE |
| Shalby Medicos Trust | Bulk | 2022-05-30 |
Sell |
107.50 | 700,000 | NSE |
| Olga Trading Private Limited | Bulk | 2021-07-05 |
Purchase |
192.02 | 542,690 | NSE |
| Olga Trading Private Limited | Bulk | 2021-07-05 |
Sell |
191.35 | 537,690 | NSE |
| Shree Shivshakti Project Consultant Private Limite | Bulk | 2020-12-24 |
Purchase |
112.07 | 616,755 | NSE |
| Shree Shivshakti Project Consultant Private Limite | Bulk | 2020-12-24 |
Sell |
112.16 | 616,223 | NSE |
| Goldman Sachs India Fund Ltd | Bulk | 2020-04-03 |
Sell |
43.03 | 1,300,000 | NSE |
| Goldman Sachs India Fund Limited | Bulk | 2020-04-03 |
Sell |
43.04 | 1,231,536 | BSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| Vikram Indrajit Shah | Promoter and Director |
Acquisition |
2026-08-21 | 5,000 | 8,010,493 | 154.72 | Insider Trading | Market Purchase |
| Shah Family Trust | Promoter |
Acquisition |
2025-10-14 | 60,000 | 37,577,132 | SAST 29(2) | Market | |
| Shah Family Trust Through Dr. Vikram I Shah, Trustee | Promoter |
Acquisition |
2025-09-20 | 60,000 | 37,577,132 | 240.18 | Insider Trading | Market Purchase |
| Dr Vikram Shah | Promoter |
Acquisition |
2024-11-22 | 25,000 | 8,005,493 | SAST 29(2) | Market | |
| Dr. Vikram Indrajit Shah | Promoter & Director |
Acquisition |
2024-11-15 | 25,000 | 8,005,493 | 218.19 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2024-06-27 | 10,000 | 7,980,493 | SAST 29(2) | Market | |
| Dr. Vikram Indrajit Shah | Promoter & Director |
Acquisition |
2024-06-06 | 10,000 | 7,980,493 | 254.16 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2024-03-14 | 125,000 | 7,970,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter & Director |
Acquisition |
2024-03-07 | 125,000 | 7,970,493 | 244.20 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2022-12-12 | 30,000 | 7,845,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter |
Acquisition |
2022-12-08 | 30,000 | 7,845,493 | 149.63 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2022-12-05 | 20,000 | 7,815,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter |
Acquisition |
2022-11-29 | 20,000 | 7,815,493 | 151.67 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2022-11-22 | 20,000 | 7,795,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter |
Acquisition |
2022-11-17 | 20,000 | 7,795,493 | 143.51 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2022-11-07 | 20,000 | 7,775,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter |
Acquisition |
2022-11-04 | 20,000 | 7,775,493 | 144.88 | Insider Trading | Market Purchase |
| Neelu Pratik Kedia | Directors Immediate Relative |
Disposal |
2022-10-27 | 530 | 0 | 145.13 | Insider Trading | Market Sale |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2022-06-16 | 10,000 | 7,755,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter |
Acquisition |
2022-06-14 | 10,000 | 7,755,493 | 111.55 | Insider Trading | Market Purchase |
| Dr Vikram Indrajit Shah | Promoter |
Acquisition |
2022-06-02 | 10,000 | 7,745,493 | SAST 29(2) | Market | |
| Vikram Indrajit Shah | Promoter |
Acquisition |
2022-06-01 | 10,000 | 7,745,493 | 111.27 | Insider Trading | Market Purchase |
| Shalby Limited Employees Welfare Trust | Trust |
Acquisition |
2022-05-31 | 700,000 | 700,000 | 107.75 | Insider Trading | Market Purchase |
About Shalby Ltd
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Shalby Limited was originally incorporated as a Private Limited Company with the name `Shalby Hospital Private Limited` on August 30, 2004. Subsequently, the Company was converted to a Public Limited Company and the name was changed to `Shalby Hospital Public Limited` on May 15, 2006. Further, the name of the Company was changed to Shalby Hospitals Limited on July 26, 2006 and then, again changed to Shalby Limited on February 13, 2008. Shalby Limited is an Ahmedabad-headquartered and one of the leading multi-specialty chain of hospitals in India and provides high-quality and economical healthcare services. With 15 hospitals and over 2,300 beds across 12 cities, Shalby is now the largest corporate hospital group in Western and Central India. The Hospitals are tertiary care hospitals, few of which offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations. Led by Dr. Vikram Shah, an orthopaedic surgeon, the Hospital has grown from a single hospital to a chain of multi-specialty hospitals. Apart from orthopaedics, the hospitals provide advanced levels of care across various specialties such as neurology, cardiac care, critical care, oncology, and nephrology. The Hospitals, Krishna Shalby, SG Shalby, Shalby Indore and Shalby Jabalpur are accredited by the NABH. Further, Krishna Shalby and SG Shalby are also accredited by the NABL. The Hospital currently runs a pan-Indian chain of 11 multispecialty tertiary hospitals and 4 Single specialty Hospitals (SOCE) across 6 states with a total bed capacity of more than 2,000. Shalby has 59 outpatient clinics (OPDs) across 16 states. It also expanded global presence by opening OPDs in Kenya, Nairobi, Ethiopia, Tanzania, and Uganda in the African continent. In 2007, the Company established operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad. The company commenced a new hospital Shalby Vapi at Vapi in April 2012 and thereafter it commenced a new hospital Krishna Shalby in Ahmedabad in October 2012. The company commenced a new hospital Shalby Jabalpur at Jabalpur in Madhya Pradesh in March 2015. The company commenced a new hospital Shalby Indore at Indore in August 2015. In 2016, the company executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby. During the year under review, the company executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali. In 2017, the company entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries. The Company came up with an Initial Public Offer of 20,354,838 Equity Shares by raising capital from public aggregating to Rs 504. 8 Crores comprising a Fresh Issue of 19,354,838 Equity Shares amounting to Rs 480 Crores and an Offer for Sale of 1,000,000 Equity Shares amounting to Rs 24.8 Crore in December, 2017. With the increase in demand of digital transformation in healthcare sector, Shalby embarked its journey of digital transformation across its all hospitals from 2018-19. In 2020, the Company launched Video Assisted Thoracic Surgery (VATS) to reduce the incidence of surgical complications. The Liver Transplant Facility became fully operational at Shalby, Ahmedabad and Mohali. The Company incorporated a new wholly owned subsidiary Company under the name and style `Mars Medical Devices Limited` on April 3, 2020. The Company also incorporated wholly-owned subsidiary company under the name and style `Shalby Hospitals Mumbai Pvt. Ltd.` on December 10, 2020. In May 2021, the Company acquired the assets of Consensus Orthopaedics, a hip and knee implant manufacturing company with its facility at El Dorado Hills, USA. The Company also commenced multi-speciality rehabilitation centre at one of its Unit in 2021. The Company launched a state-of-the-art `Digital Spine Operation Room` at SG Shalby Hospital, Ahmedabad in 2022. In September 2021, the Company launched its first Shalby Orthopedics Centre of Excellence (SOCE) in the country at Udaipur. Centralised cloud based Laboratory Information System (LIS) was launched in 2022. The Company further incorporated Shalby Advanced Technologies Inc. (SAT) in the first quarter of Fiscal 2022. In 2022-23, the Company launched a new product line of Uni Knee System called as Tahoe Unicompartmental Knee System or TUKS. It acquired 87.26% stake in PK Healthcare Pvt Ltd (Sanar International Hospital-130 beds) in FY 2024, making it a subsidiary of the Company and further acquired 100% stake in Healers Hospital Pvt Ltd at Gurugram costing Rs 104 Crore. Company further has established new SOCE in Ranchi having 60 beds in 2024. The new Rajkot SOCE unit became operational from July 2024. The Company opened major units at Indore and other hospitals to strengthen the super-speciality capabilities, supported by the hiring of 40 doctors focused on high-end procedures. Sanar Shalby Hospital in Gurugram, enhanced a Centre of Excellence (CoE) for liver transplants, bone marrow transplants, CT transplants and complex procedures in FY 2025.
Shalby share price as on 23 Sep 2026 is Rs. 136.7. Over the past 6 months, the Shalby share price has decreased by 2.41% and in the last one year, it has decreased by 48.54%. The 52-week low for Shalby share price was Rs. 125.82 and 52-week high was Rs. 273.
Opp Karnawati Club, Sarkhej Gandhinagar Highway, Ahmedabad, Gujarat, 380015
Tel No. 91-79-40203000
Email companysecretary:shalby.in
Independent Non Exe. Director
Chairman / Executive Director / M D / Promoter
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
Independent Non Exe. Director
CS / CO / AVP
540797
SHALBY
INE597J01018
Sep
Shalby Ltd FAQs
You can buy Shalby Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Shalby Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 22, 2026 03:57 PM the closing price of Shalby Ltd was Rs.136.70.
The latest PE ratio of Shalby Ltd as of Sep 22, 2026 03:57 PM is 39.54
The latest PB ratio of Shalby Ltd as of Sep 22, 2026 03:57 PM is 1.47
The 52-week high of Shalby Ltd share price is Rs. 273.00 while the 52-week low is Rs. 125.82
According to analyst recommendations, Shalby Ltd Share has a "Buy" rating for the long term.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 22, 2026 03:57 PM, the market cap of Shalby Ltd stood at Rs. 1,476.50 Cr.
Market Outlook
View all
Navneet Munot on Inevitable India, Deep Tech, Artificial Intelligence and the Next Phase of Wealth Creation
ICICI Securities Ltd - INZ000183631 At the India Investor Conference 2026, an engaging Ask Me Anything session brought together investors and market participants for a conversation with Navneet ...
India Investor Conference 2026 : India's Power Infrastructure Boom and Data Center Growth Opportunity
ICICI Securities Ltd - INZ000183631 At the India Investor Conference 2026, Kushal Desai, Chairman and Managing Director of APAR Industries, shared his perspective on the forces reshaping the global po...
India Investor Conference 2026 - Deep dive into the Electronics Manufacturing Industry
ICICI Securities Ltd - INZ000183631 How India’s Electronics Manufacturing Industry Is Moving Beyond Assembly to Become a Global Design and Engineering Hub At the India Investor Conference 2026, ...
India Investor Conference 2026 - Professor V. Kamakoti on Building a Technology Superpower Through Startups, Innovation and Deep Tech
ICICI Securities Ltd - INZ000183631 Speaking at the India Investor Conference 2026, Professor V. Kamakoti, Director, IIT Madras, shared his perspective on how academic institutions, industry leaders a...